Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 21.83% is 315% above its 5-year average of -10.13%, near the high end of its 5-year range (-36.74%–25.00%).
0.93% below its 12-month average of 22.04%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 1.81%.
RETURN ON ASSETS (ROA)
21.83%
RETURN ON ASSETS (ROA) AVG TTM
22.04%
RETURN ON ASSETS (ROA) AVG 3Y
-0.21%
RETURN ON ASSETS (ROA) AVG 5Y
-10.13%
RETURN ON ASSETS (ROA) AVG 10Y
-30.36%
RETURN ON ASSETS (ROA) AVG 15Y
-31.50%
RETURN ON ASSETS (ROA) AVG 20Y
-40.48%
CURRENT VS TTM AVG
-0.93%
CURRENT VS 3Y AVG
+10372.94%
CURRENT VS 5Y AVG
+315.39%
CURRENT VS 10Y AVG
+171.90%
CURRENT VS 15Y AVG
+169.29%
CURRENT VS 20Y AVG
+153.93%
SECTOR MEDIAN · HEALTHCARE
-23.55%
median of 388 covered companies
CURRENT VS SECTOR MEDIAN
+192.68%
vs the sector median at left
Acadia Pharmaceuticals Inc.
Market Cap
$3.44B
Return on Assets (ROA)
21.83%
TTM Avg
22.04%
3Y Avg
-0.21%
5Y Avg
-10.13%
Market Cap
$3.59B
Return on Assets (ROA)
-27.35%
TTM Avg
-41.78%
3Y Avg
-34.97%
5Y Avg
-41.24%
Market Cap
$3.61B
Return on Assets (ROA)
20.83%
TTM Avg
2.76%
3Y Avg
-12.34%
5Y Avg
-9.97%
Market Cap
$3.25B
Return on Assets (ROA)
-11.64%
TTM Avg
-24.55%
3Y Avg
-30.16%
5Y Avg
-27.23%
Market Cap
$3.16B
Return on Assets (ROA)
-44.17%
TTM Avg
-37.77%
3Y Avg
-27.61%
5Y Avg
-21.12%
Market Cap
$3.15B
Return on Assets (ROA)
5.84%
TTM Avg
-21.93%
3Y Avg
-47.49%
5Y Avg
-47.67%
Market Cap
$3.09B
Return on Assets (ROA)
-57.49%
TTM Avg
-99.67%
3Y Avg
-60.13%
5Y Avg
-103.92%
Market Cap
$2.88B
Return on Assets (ROA)
-52.25%
TTM Avg
-41.76%
3Y Avg
-70.33%
5Y Avg
-55.50%
Market Cap
$2.87B
Return on Assets (ROA)
10.36%
TTM Avg
11.11%
3Y Avg
1.40%
5Y Avg
-7.68%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acadia Pharmaceuticals Inc. (ACAD) | $3.44B | 21.83% | 22.04% | -0.21% | -10.13% |
| Celcuity Inc. (CELC)vs › | $3.59B | -27.35% | -41.78% | -34.97% | -41.24% |
| CareDx, Inc (CDNA)vs › | $3.61B | 20.83% | 2.76% | -12.34% | -9.97% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | -11.64% | -24.55% | -30.16% | -27.23% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | -44.17% | -37.77% | -27.61% | -21.12% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | 5.84% | -21.93% | -47.49% | -47.67% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | -57.49% | -99.67% | -60.13% | -103.92% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -52.25% | -41.76% | -70.33% | -55.50% |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 10.36% | 11.11% | 1.40% | -7.68% |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 1.56% | -4.54% | -5.50% | -3.43% |
ROA
21.8%
ROE
29.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 25.00% |
| 2024-12-31 | 19.07% |
| 2023-12-31 | -8.18% |
| 2022-12-31 | -36.74% |
| 2021-12-31 | -23.98% |
| 2020-12-31 | -35.98% |
| 2019-12-31 | -30.04% |
| 2018-12-31 | -45.39% |
| 2017-12-31 | -75.27% |
| 2016-12-31 | -48.36% |
| 2015-12-31 | -74.11% |
| 2014-12-31 | -28.41% |
| 2013-12-31 | -20.07% |
| 2012-12-31 | -19.20% |
| 2011-12-31 | -70.89% |
| 2010-12-31 | 39.43% |
| 2009-12-31 | -90.87% |
| 2008-12-31 | -99.33% |
| 2007-12-31 | -41.90% |
| 2006-12-31 | -50.31% |
| 2005-12-31 | -54.61% |
| 2004-12-31 | -64.21% |
| 2003-12-31 | -44.47% |
| 2002-12-31 | -80.31% |
| 2001-12-31 | -65.60% |
| 2000-12-31 | -29.88% |
